Marfan syndrome: genetic variant determinants of cardiovascular outcomes

Abstract Background Marfan syndrome is a systemic connective tissue disorder caused by genetic variants in the fibrillin-1 (FBN1) gene. Cardiovascular complications are the leading cause of mortality. Purpose To compare cardiovascular outcome by gender and by type of the genetic variant in the FBN1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2021-10, Vol.42 (Supplement_1)
Hauptverfasser: Brogger, M N, Fernandez Ferro, G, Cardenas Reyes, I, Ochoa, J P, Garcia Hernandez, S, Fernandez, X, Garcia Giustiniani, D, Lamounier, A, Valverde, M, De La Higuera Romero, L, Ortiz Genga, M, Monserrat, L, McKenna, W J
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title European heart journal
container_volume 42
creator Brogger, M N
Fernandez Ferro, G
Cardenas Reyes, I
Ochoa, J P
Garcia Hernandez, S
Fernandez, X
Garcia Giustiniani, D
Lamounier, A
Valverde, M
De La Higuera Romero, L
Ortiz Genga, M
Monserrat, L
McKenna, W J
description Abstract Background Marfan syndrome is a systemic connective tissue disorder caused by genetic variants in the fibrillin-1 (FBN1) gene. Cardiovascular complications are the leading cause of mortality. Purpose To compare cardiovascular outcome by gender and by type of the genetic variant in the FBN1 gene. Materials and methods We analyzed clinical data on 1956 carriers and affected relatives with 1430 pathogenic or likely pathogenic genetic variants in the FBN1 gene (including cases identified in our laboratory and cases described in the literature) in whom age at last follow-up was available. We excluded patients with pathogenic or likely pathogenic genetic variants located in the so-called “neonatal region” (exon 24–32); they are recognized to have an early onset/severe phenotype. Kaplan-Meier survival curves were generated to examine gender and type of genetic variant in relation to survival free of surgical intervention or cardiovascular (CV) death (composite of deaths related to aortic dissection, heart failure/transplant, sudden, stroke or CV surgery). Genetic variants were classified as truncating (nonsense, frameshift and splicing), “missense non-neonatal” and only those missense eliminating a Cysteine residue in the non-neonatal region (“Cys non-neonatal”). Results Data were examined on 896 patients with truncating variants (53% male; 47% female) and 1060 with missense variants, located outside the “neonatal region” (54% male; 46% female). Of these, 475 were missense variants substituting a cysteine residue (52% male; 48% female). Those with truncating variants had worse prognosis versus those with missense and Cys variants (p=0.000108 and p=0.000115), with earlier onset of cardiovascular events. Overall, patients with missense variants had similar prognosis to those with missense variants eliminating a Cysteine residue. By age 65, however, almost 50% of patients with any type of variant had suffered a CV event, and with each variant type males had worse prognosis (see Figure 1). This was most evident in males aged 30 to 50 with missense variants that substituted a Cysteine residue, while female carriers of these variants had a prognosis similar to other missense variants (see Figure 2). During the first decade carriers of missense and truncating variants mainly died of heart failure. From age 10 to 50, aortic dissection was the most common event, while later other events became more frequent, e.g. vascular intervention and sudden death. Conclusion
doi_str_mv 10.1093/eurheartj/ehab724.1987
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_ehab724_1987</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehab724.1987</oup_id><sourcerecordid>10.1093/eurheartj/ehab724.1987</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1377-6e1a9714999fcff59b1f6fa343dc5c0b0785094e986f54726b980320bcbd312c3</originalsourceid><addsrcrecordid>eNqN0M1Kw0AUhuFBFKzVW5C5gbRzMpk_d1LUChU3Cu7CmcmMTWmSMpMUevemtHTt6pzN-y0eQh6BzYAZPvdDXHuM_Wbu12hVXszAaHVFJiDyPDOyENdkwsCITEr9c0vuUtowxrQEOSHLD4wBW5oObRW7xj_RX9_6vnZ0j7HGtqeV731s6nb8E-0CdRiruttjcsMWI-2G3o1duic3AbfJP5zvlHy_vnwtltnq8-198bzKHHClMukBjYLCGBNcCMJYCDIgL3jlhGOWKS2YKbzRMohC5dIazXjOrLMVh9zxKZGnXRe7lKIP5S7WDcZDCaw8epQXj_LsUR49xhBOYTfs_tv8AcmMahA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Marfan syndrome: genetic variant determinants of cardiovascular outcomes</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Brogger, M N ; Fernandez Ferro, G ; Cardenas Reyes, I ; Ochoa, J P ; Garcia Hernandez, S ; Fernandez, X ; Garcia Giustiniani, D ; Lamounier, A ; Valverde, M ; De La Higuera Romero, L ; Ortiz Genga, M ; Monserrat, L ; McKenna, W J</creator><creatorcontrib>Brogger, M N ; Fernandez Ferro, G ; Cardenas Reyes, I ; Ochoa, J P ; Garcia Hernandez, S ; Fernandez, X ; Garcia Giustiniani, D ; Lamounier, A ; Valverde, M ; De La Higuera Romero, L ; Ortiz Genga, M ; Monserrat, L ; McKenna, W J</creatorcontrib><description>Abstract Background Marfan syndrome is a systemic connective tissue disorder caused by genetic variants in the fibrillin-1 (FBN1) gene. Cardiovascular complications are the leading cause of mortality. Purpose To compare cardiovascular outcome by gender and by type of the genetic variant in the FBN1 gene. Materials and methods We analyzed clinical data on 1956 carriers and affected relatives with 1430 pathogenic or likely pathogenic genetic variants in the FBN1 gene (including cases identified in our laboratory and cases described in the literature) in whom age at last follow-up was available. We excluded patients with pathogenic or likely pathogenic genetic variants located in the so-called “neonatal region” (exon 24–32); they are recognized to have an early onset/severe phenotype. Kaplan-Meier survival curves were generated to examine gender and type of genetic variant in relation to survival free of surgical intervention or cardiovascular (CV) death (composite of deaths related to aortic dissection, heart failure/transplant, sudden, stroke or CV surgery). Genetic variants were classified as truncating (nonsense, frameshift and splicing), “missense non-neonatal” and only those missense eliminating a Cysteine residue in the non-neonatal region (“Cys non-neonatal”). Results Data were examined on 896 patients with truncating variants (53% male; 47% female) and 1060 with missense variants, located outside the “neonatal region” (54% male; 46% female). Of these, 475 were missense variants substituting a cysteine residue (52% male; 48% female). Those with truncating variants had worse prognosis versus those with missense and Cys variants (p=0.000108 and p=0.000115), with earlier onset of cardiovascular events. Overall, patients with missense variants had similar prognosis to those with missense variants eliminating a Cysteine residue. By age 65, however, almost 50% of patients with any type of variant had suffered a CV event, and with each variant type males had worse prognosis (see Figure 1). This was most evident in males aged 30 to 50 with missense variants that substituted a Cysteine residue, while female carriers of these variants had a prognosis similar to other missense variants (see Figure 2). During the first decade carriers of missense and truncating variants mainly died of heart failure. From age 10 to 50, aortic dissection was the most common event, while later other events became more frequent, e.g. vascular intervention and sudden death. Conclusion In our cohort, male carriers of pathogenic or likely pathogenic variants had worse prognosis versus females. Carriers of truncating variants had the worst CV outcomes. However, it is noteworthy that by age 65, regardless of gender or mutation type, close to 50% of patients had experienced a major CV event/death. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Health in Code Figure 2. Type by gender</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehab724.1987</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2021-10, Vol.42 (Supplement_1)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids></links><search><creatorcontrib>Brogger, M N</creatorcontrib><creatorcontrib>Fernandez Ferro, G</creatorcontrib><creatorcontrib>Cardenas Reyes, I</creatorcontrib><creatorcontrib>Ochoa, J P</creatorcontrib><creatorcontrib>Garcia Hernandez, S</creatorcontrib><creatorcontrib>Fernandez, X</creatorcontrib><creatorcontrib>Garcia Giustiniani, D</creatorcontrib><creatorcontrib>Lamounier, A</creatorcontrib><creatorcontrib>Valverde, M</creatorcontrib><creatorcontrib>De La Higuera Romero, L</creatorcontrib><creatorcontrib>Ortiz Genga, M</creatorcontrib><creatorcontrib>Monserrat, L</creatorcontrib><creatorcontrib>McKenna, W J</creatorcontrib><title>Marfan syndrome: genetic variant determinants of cardiovascular outcomes</title><title>European heart journal</title><description>Abstract Background Marfan syndrome is a systemic connective tissue disorder caused by genetic variants in the fibrillin-1 (FBN1) gene. Cardiovascular complications are the leading cause of mortality. Purpose To compare cardiovascular outcome by gender and by type of the genetic variant in the FBN1 gene. Materials and methods We analyzed clinical data on 1956 carriers and affected relatives with 1430 pathogenic or likely pathogenic genetic variants in the FBN1 gene (including cases identified in our laboratory and cases described in the literature) in whom age at last follow-up was available. We excluded patients with pathogenic or likely pathogenic genetic variants located in the so-called “neonatal region” (exon 24–32); they are recognized to have an early onset/severe phenotype. Kaplan-Meier survival curves were generated to examine gender and type of genetic variant in relation to survival free of surgical intervention or cardiovascular (CV) death (composite of deaths related to aortic dissection, heart failure/transplant, sudden, stroke or CV surgery). Genetic variants were classified as truncating (nonsense, frameshift and splicing), “missense non-neonatal” and only those missense eliminating a Cysteine residue in the non-neonatal region (“Cys non-neonatal”). Results Data were examined on 896 patients with truncating variants (53% male; 47% female) and 1060 with missense variants, located outside the “neonatal region” (54% male; 46% female). Of these, 475 were missense variants substituting a cysteine residue (52% male; 48% female). Those with truncating variants had worse prognosis versus those with missense and Cys variants (p=0.000108 and p=0.000115), with earlier onset of cardiovascular events. Overall, patients with missense variants had similar prognosis to those with missense variants eliminating a Cysteine residue. By age 65, however, almost 50% of patients with any type of variant had suffered a CV event, and with each variant type males had worse prognosis (see Figure 1). This was most evident in males aged 30 to 50 with missense variants that substituted a Cysteine residue, while female carriers of these variants had a prognosis similar to other missense variants (see Figure 2). During the first decade carriers of missense and truncating variants mainly died of heart failure. From age 10 to 50, aortic dissection was the most common event, while later other events became more frequent, e.g. vascular intervention and sudden death. Conclusion In our cohort, male carriers of pathogenic or likely pathogenic variants had worse prognosis versus females. Carriers of truncating variants had the worst CV outcomes. However, it is noteworthy that by age 65, regardless of gender or mutation type, close to 50% of patients had experienced a major CV event/death. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Health in Code Figure 2. Type by gender</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqN0M1Kw0AUhuFBFKzVW5C5gbRzMpk_d1LUChU3Cu7CmcmMTWmSMpMUevemtHTt6pzN-y0eQh6BzYAZPvdDXHuM_Wbu12hVXszAaHVFJiDyPDOyENdkwsCITEr9c0vuUtowxrQEOSHLD4wBW5oObRW7xj_RX9_6vnZ0j7HGtqeV731s6nb8E-0CdRiruttjcsMWI-2G3o1duic3AbfJP5zvlHy_vnwtltnq8-198bzKHHClMukBjYLCGBNcCMJYCDIgL3jlhGOWKS2YKbzRMohC5dIazXjOrLMVh9zxKZGnXRe7lKIP5S7WDcZDCaw8epQXj_LsUR49xhBOYTfs_tv8AcmMahA</recordid><startdate>20211012</startdate><enddate>20211012</enddate><creator>Brogger, M N</creator><creator>Fernandez Ferro, G</creator><creator>Cardenas Reyes, I</creator><creator>Ochoa, J P</creator><creator>Garcia Hernandez, S</creator><creator>Fernandez, X</creator><creator>Garcia Giustiniani, D</creator><creator>Lamounier, A</creator><creator>Valverde, M</creator><creator>De La Higuera Romero, L</creator><creator>Ortiz Genga, M</creator><creator>Monserrat, L</creator><creator>McKenna, W J</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20211012</creationdate><title>Marfan syndrome: genetic variant determinants of cardiovascular outcomes</title><author>Brogger, M N ; Fernandez Ferro, G ; Cardenas Reyes, I ; Ochoa, J P ; Garcia Hernandez, S ; Fernandez, X ; Garcia Giustiniani, D ; Lamounier, A ; Valverde, M ; De La Higuera Romero, L ; Ortiz Genga, M ; Monserrat, L ; McKenna, W J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1377-6e1a9714999fcff59b1f6fa343dc5c0b0785094e986f54726b980320bcbd312c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brogger, M N</creatorcontrib><creatorcontrib>Fernandez Ferro, G</creatorcontrib><creatorcontrib>Cardenas Reyes, I</creatorcontrib><creatorcontrib>Ochoa, J P</creatorcontrib><creatorcontrib>Garcia Hernandez, S</creatorcontrib><creatorcontrib>Fernandez, X</creatorcontrib><creatorcontrib>Garcia Giustiniani, D</creatorcontrib><creatorcontrib>Lamounier, A</creatorcontrib><creatorcontrib>Valverde, M</creatorcontrib><creatorcontrib>De La Higuera Romero, L</creatorcontrib><creatorcontrib>Ortiz Genga, M</creatorcontrib><creatorcontrib>Monserrat, L</creatorcontrib><creatorcontrib>McKenna, W J</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brogger, M N</au><au>Fernandez Ferro, G</au><au>Cardenas Reyes, I</au><au>Ochoa, J P</au><au>Garcia Hernandez, S</au><au>Fernandez, X</au><au>Garcia Giustiniani, D</au><au>Lamounier, A</au><au>Valverde, M</au><au>De La Higuera Romero, L</au><au>Ortiz Genga, M</au><au>Monserrat, L</au><au>McKenna, W J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Marfan syndrome: genetic variant determinants of cardiovascular outcomes</atitle><jtitle>European heart journal</jtitle><date>2021-10-12</date><risdate>2021</risdate><volume>42</volume><issue>Supplement_1</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract Background Marfan syndrome is a systemic connective tissue disorder caused by genetic variants in the fibrillin-1 (FBN1) gene. Cardiovascular complications are the leading cause of mortality. Purpose To compare cardiovascular outcome by gender and by type of the genetic variant in the FBN1 gene. Materials and methods We analyzed clinical data on 1956 carriers and affected relatives with 1430 pathogenic or likely pathogenic genetic variants in the FBN1 gene (including cases identified in our laboratory and cases described in the literature) in whom age at last follow-up was available. We excluded patients with pathogenic or likely pathogenic genetic variants located in the so-called “neonatal region” (exon 24–32); they are recognized to have an early onset/severe phenotype. Kaplan-Meier survival curves were generated to examine gender and type of genetic variant in relation to survival free of surgical intervention or cardiovascular (CV) death (composite of deaths related to aortic dissection, heart failure/transplant, sudden, stroke or CV surgery). Genetic variants were classified as truncating (nonsense, frameshift and splicing), “missense non-neonatal” and only those missense eliminating a Cysteine residue in the non-neonatal region (“Cys non-neonatal”). Results Data were examined on 896 patients with truncating variants (53% male; 47% female) and 1060 with missense variants, located outside the “neonatal region” (54% male; 46% female). Of these, 475 were missense variants substituting a cysteine residue (52% male; 48% female). Those with truncating variants had worse prognosis versus those with missense and Cys variants (p=0.000108 and p=0.000115), with earlier onset of cardiovascular events. Overall, patients with missense variants had similar prognosis to those with missense variants eliminating a Cysteine residue. By age 65, however, almost 50% of patients with any type of variant had suffered a CV event, and with each variant type males had worse prognosis (see Figure 1). This was most evident in males aged 30 to 50 with missense variants that substituted a Cysteine residue, while female carriers of these variants had a prognosis similar to other missense variants (see Figure 2). During the first decade carriers of missense and truncating variants mainly died of heart failure. From age 10 to 50, aortic dissection was the most common event, while later other events became more frequent, e.g. vascular intervention and sudden death. Conclusion In our cohort, male carriers of pathogenic or likely pathogenic variants had worse prognosis versus females. Carriers of truncating variants had the worst CV outcomes. However, it is noteworthy that by age 65, regardless of gender or mutation type, close to 50% of patients had experienced a major CV event/death. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Health in Code Figure 2. Type by gender</abstract><pub>Oxford University Press</pub><doi>10.1093/eurheartj/ehab724.1987</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2021-10, Vol.42 (Supplement_1)
issn 0195-668X
1522-9645
language eng
recordid cdi_crossref_primary_10_1093_eurheartj_ehab724_1987
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
title Marfan syndrome: genetic variant determinants of cardiovascular outcomes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T01%3A01%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Marfan%20syndrome:%20genetic%20variant%20determinants%20of%20cardiovascular%20outcomes&rft.jtitle=European%20heart%20journal&rft.au=Brogger,%20M%20N&rft.date=2021-10-12&rft.volume=42&rft.issue=Supplement_1&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehab724.1987&rft_dat=%3Coup_cross%3E10.1093/eurheartj/ehab724.1987%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/eurheartj/ehab724.1987&rfr_iscdi=true